PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData

The European Commission (EC) recently approved GSK’s novel vaccine, Arexvy, for the prevention of lower respiratory tract infections (LRTI) caused by a respiratory syncytial virus (RSV) in adults 60 years of age and older, making it the first RSV vaccine available across the EU. Arexvy was also approved by the FDA in May, becoming the first RSV vaccine authorized for use in the US. Despite these landmark approvals, GSK’s dominance in the untapped RSV vaccine space is under threat. Pfizer, in hot pursuit of a market share of its own RSV vaccine, Abrysvo, approved by the FDA just weeks after Arexvy, is likely to show GSK significant competition, says GlobalData, a leading data and analytics company. 

Nancy Jaser, Pharma Analyst at GlobalData, comments: “While Arexvy was first to gain US approval, which marked the first time a vaccine was authorized for use against RSV in any population, anywhere in the world, Pfizer’s Abrysvo was approved by the FDA quickly after, allowing sufficient time for both vaccines to be available for US launch around the same time this fall, prior to the winter RSV season. Therefore, GSK is not likely to experience a significant first-mover advantage for market share in the US. However, Arexvy may still benefit from a first-mover advantage in the EU as Pfizer’s Abrysvo has yet to gain approval for use by the EC. A decision is expected later this year.”

While both vaccines demonstrated high efficacy in pivotal trials, Pfizer’s vaccine has one critical advantage over Arexvy. Abrysvo is currently under review in the US as a maternal vaccine to protect infants against RSV right at birth. The FDA’s Vaccines Advisory Committee voted in favor of approving Abrysvo as a maternal RSV vaccine and a PDUFA date is set for this coming August.

Jaser continues: “Abrysvo will likely be the first approved RSV vaccine to protect infants worldwide, potentially leading to a higher market share than its competitors. It is currently the only vaccine candidate in late-stage development that targets multiple patient segments.”

Further competition is expected from Moderna’s RSV vaccine, mRNA-1345. Positive Phase III data in older adults were announced in January, while Moderna plans to file for US approval in the first half of 2023.

Jaser concludes: “mRNA-1345 is likely to be the first mRNA-based RSV vaccine to reach the market. As an RNA virus, RSV is capable of rapid mutation to escape attack by new pharmaceuticals. Novel RSV variants could emerge as a result, requiring adjustments to vaccine targets. Moderna’s vaccine would likely see higher success in this situation, as the mRNA platform allows for quick modification of antigens to target potential new viral strains.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026